Clinical Trials Logo

Leukemia, Myeloid clinical trials

View clinical trials related to Leukemia, Myeloid.

Filter by:

NCT ID: NCT02203773 Terminated - Clinical trials for Acute Myelogenous Leukemia

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

Start date: October 6, 2014
Phase: Phase 1
Study type: Interventional

This is a Phase 1b, open-label, non-randomized, multicenter study to evaluate the safety and pharmacokinetics of orally administered venetoclax (ABT-199) combined with decitabine or azacitidine and the preliminary efficacy of these combinations. In addition, there is a drug-drug interaction (DDI) sub-study only at a single site, to assess the pharmacokinetics and safety of venetoclax (ABT-199) in combination with posaconazole.

NCT ID: NCT02200380 Terminated - Clinical trials for Myelodysplastic Syndrome (MDS)

A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs

Start date: July 2014
Phase: Phase 2
Study type: Interventional

This is an open-label, multicenter, prospective pilot study of CDX-301 with or without plerixafor as a stem cell mobilizer for allogeneic transplantation (stem cells that come from another person). HLA-matched sibling healthy volunteers (donors) and patients with protocol specified hematologic malignancies (recipients) will be enrolled.

NCT ID: NCT02198482 Terminated - Clinical trials for Acute Myeloid Leukemia (AML)

Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Start date: February 2016
Phase: Phase 2
Study type: Interventional

Randomized Phase II Trial of Intensive Chemotherapy With or Without Volasertib (BI 6727) in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

NCT ID: NCT02197676 Completed - MDS Clinical Trials

A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response

Start date: August 4, 2014
Phase: Phase 2
Study type: Interventional

Treatment of patients with WHO defined IPSS int 2 and high risk MDS , AML with 20-30% marrow blasts and CMML type 2, after failure of azacitidine or decitabine exposure for at least 6 courses, or relapse after initial response.

NCT ID: NCT02196857 Completed - Leukemia Clinical Trials

Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation

Start date: February 6, 2015
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if 5-azacitidine and sorafenib can help to control the disease in patients with Acute Myeloid Leukemia (AML) and high risk Myelodisplastic Syndrome (MDS) with FLT3-ITD mutation. The safety of this drug combination will also be studied.

NCT ID: NCT02190695 Completed - Clinical trials for Acute Myeloid Leukemia

Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS

Start date: April 1, 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find a new way to treat Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML). All the drugs are used to treat AML and MDS but are not usually combined together. The investigators are looking at both the safety and Efficacy of each combination.

NCT ID: NCT02188706 Active, not recruiting - Leukemia Clinical Trials

A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin and Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Start date: July 2014
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to compare the response rates of patients receiving decitabine alone, decitabine with carboplatin, and decitabine with arsenic trioxide in patients with AML or MDS.

NCT ID: NCT02182596 Completed - Clinical trials for Acute Myeloid Leukemia

DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML

MYLOFRANCE2
Start date: June 2006
Phase: Phase 1/Phase 2
Study type: Interventional

For several years, the effective standard induction chemotherapy for AML has been limited to the association of anthracycline and aracytine. GO is the first effective targeted antibody used in leukemia patients. In a previous study, we showed efficacy and safety of fractionated doses of GO used as a single agent for treatment of adult AML patients in first relapse. In the present study the possibility of combining fractionated doses of GO to escalated doses of a 3+7 regimen old is studied in relapsed AML patients > 50 and <70 years.

NCT ID: NCT02181699 Terminated - Clinical trials for Acute Myeloid Leukemia

Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Start date: June 2014
Phase: Phase 1
Study type: Interventional

This is a first in human, non-randomized, open-label, dose escalation study to investigate the safety, pharmacokinetics, immunogenicity and pharmacodynamics of repeat doses of KHK2823.

NCT ID: NCT02181660 Completed - Clinical trials for Acute Myeloid Leukemia (AML)

Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia

Start date: June 16, 2014
Phase: Phase 1
Study type: Interventional

The objectives of this study are to determine the safety and tolerability of ASP2215 as well as the maximum tolerated dose (MTD) based on the onset of dose limiting toxicity (DLT) and/or determine the recommended dose (RD) of ASP2215 for the next phase in subjects with relapsed or treatment-refractory acute myeloid leukemia (AML).